Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
8.00
-0.09 (-1.11%)
At close: Feb 21, 2025, 4:00 PM
8.10
+0.10 (1.25%)
After-hours: Feb 21, 2025, 5:42 PM EST
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cogent Biosciences stock have an average target of 14.17, with a low estimate of 10 and a high estimate of 21. The average target predicts an increase of 77.13% from the current stock price of 8.00.
Analyst Consensus: Buy
* Price targets were last updated on Jan 14, 2025.
Analyst Ratings
The average analyst rating for Cogent Biosciences stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $14 | Strong Buy | Maintains | $17 → $14 | +75.00% | Jan 14, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $15 | Strong Buy → Hold | Downgrades | $15 | +87.50% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +87.50% | Dec 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +87.50% | Dec 9, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.48
from -2.42
EPS Next Year
-2.38
from -2.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 190.3M | |||
| Avg | n/a | n/a | 71.4M | |||
| Low | n/a | n/a | 2.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.40 | -1.84 | -1.23 | ||
| Avg | -2.48 | -2.38 | -1.76 | ||
| Low | -2.48 | -2.64 | -2.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.